Stockscreener 앱 받기
33.87
1.62%
0.54
시장 영업 전:
33.93
0.06
+0.18%
전일 마감가:
$33.33
열려 있는:
$33.58
하루 거래량:
971.63K
Relative Volume:
0.99
시가총액:
$2.66B
수익:
$1.55M
순이익/손실:
$-258.76M
주가수익비율:
-8.6951
EPS:
-3.8953
순현금흐름:
$-213.66M
1주 성능:
+4.50%
1개월 성능:
+14.77%
6개월 성능:
+23.88%
1년 성능:
+84.38%
1일 변동 폭
$33.49
$34.26
1주일 범위
$31.96
$34.26
52주 변동 폭
$17.45
$34.52
Celldex Therapeutics Inc Stock (CLDX) Company Profile
명칭
Celldex Therapeutics Inc
전화
908-200-7500
주소
53 FRONTAGE ROAD, HAMPTON
Compare CLDX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
33.87 | 2.62B | 1.55M | -258.76M | -213.66M | -3.8953 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-23 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-10-13 | 개시 | Barclays | Underweight |
| 2025-04-28 | 개시 | Canaccord Genuity | Buy |
| 2025-03-20 | 개시 | Morgan Stanley | Overweight |
| 2025-02-13 | 개시 | UBS | Buy |
| 2024-10-07 | 개시 | Citigroup | Buy |
| 2024-09-30 | 개시 | Goldman | Neutral |
| 2024-09-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | 개시 | Stifel | Buy |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2023-12-20 | 개시 | TD Cowen | Outperform |
| 2023-11-10 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | 개시 | Wells Fargo | Underweight |
| 2021-09-17 | 개시 | Jefferies | Buy |
| 2021-09-10 | 개시 | SVB Leerink | Outperform |
| 2021-07-22 | 개시 | Guggenheim | Buy |
| 2020-02-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-07 | 개시 | Aegis Capital | Buy |
| 2016-03-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2016-03-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2016-03-07 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2016-03-01 | 개시 | H.C. Wainwright | Buy |
| 2015-08-11 | 재확인 | Brean Capital | Buy |
| 2015-08-11 | 재확인 | Oppenheimer | Outperform |
| 2015-08-11 | 재확인 | ROTH Capital | Buy |
| 2015-06-02 | 재확인 | WBB Securities | Strong Buy |
| 2014-11-17 | 재확인 | ROTH Capital | Buy |
| 2014-03-04 | 재확인 | Oppenheimer | Outperform |
| 2013-07-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-03-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-02-26 | 재확인 | Oppenheimer | Outperform |
| 2013-01-10 | 재확인 | Cantor Fitzgerald | Buy |
| 2012-10-02 | 재확인 | Oppenheimer | Outperform |
| 2012-09-14 | 재확인 | Cantor Fitzgerald | Buy |
모두보기
Celldex Therapeutics Inc 주식(CLDX)의 최신 뉴스
Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment - MarketBeat
Celldex prices $300M stock at $29 per share to fuel Barzolvolimab launch - MSN
CLDX: Barzolvolimab shows strong, durable efficacy in urticaria with pivotal phase III data due Q4 - TradingView — Track All Markets
Celldex to Present at Upcoming Investor Conference - The Manila Times
Celldex Therapeutics announces public offering of common stock - MSN
A Look At Celldex Therapeutics (CLDX) Valuation After Equity Raise And New Barzolvolimab Data - Sahm
Precision Trading with Celldex Therapeutics Inc. (CLDX) Risk Zones - Stock Traders Daily
RSI Check: Why is Vistagen Therapeutics Inc stock going downBull Run & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Celldex Therapeutics Closes $345M Public Stock Offering - National Today
Celldex closes $345 million stock offering By Investing.com - Investing.com Australia
Celldex Therapeutics Completes $345 Million Public Offering of Common Stock - Quiver Quantitative
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares - marketscreener.com
Did Celldex’s (CLDX) US$300 Million Equity Raise to Fund Barzolvolimab Just Shift Its Investment Narrative? - Sahm
Celldex Therapeutics, Inc. (CLDX) Options Chain - Yahoo! Finance Canada
Ambrosia, Syneron move toward clinic with nine-digit series B rounds: Finance Report - biocentury.com
JPMorgan Chase & Co. Sells 49,046 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Announces Pricing of $300 Million Public Offering of Common Stock - Sahm
Celldex Therapeutics stock falls on equity offering - Investing.com
Celldex Therapeutics stock falls on equity offering By Investing.com - ca.investing.com
Celldex prices $300 million stock offering at $29 per share By Investing.com - Investing.com Australia
Celldex Therapeutics offers 10,345,000 shares of common stockSEC filing - marketscreener.com
Celldex Therapeutics (NASDAQ: CLDX) raises ~$282M net in $29 follow-on offering - Stock Titan
Celldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Celldex shares plunge after dumping $300 million stock deal - GuruFocus
Celldex Announces Major Underwritten Public Equity Offering - TipRanks
Celldex Therapeutics Inc (TCE2.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Celldex Therapeutics Prices $29 Share Sale, Expects $282 Million Net From Underwritten Offering - TradingView — Track All Markets
Celldex (NASDAQ: CLDX) raises $300M in new common stock sale - Stock Titan
Is Celldex’s US$300 Million Follow-On To Fund Barzolvolimab Altering The Investment Case For CLDX? - Yahoo Finance
Celldex launches public offering of common stock By Investing.com - Investing.com South Africa
Celldex Therapeutics Inc (TCE2.DU) Stock Price, News, Quote & History - ca.finance.yahoo.com
Celldex Therapeutics Inc (CLDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):